Ashok Narayan, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,820 of the $8,809 with a category attached, or 66.1%. AbbVie accounts for 81.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2020 at $7,412 and has fallen 97.6% since, to $174 in 2024.
Across 88 payments — averaging $100.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Argenx US, Inc.$273
- EMD Serono, Inc.$169
- SK Life Science, Inc.$160
- Greenwich Biosciences, Inc.$125
- Biogen$118
- plus $803 from 21 others
What the payments were for
- Speaking & faculty fees$5,82066%
- Travel & lodging$8339%
- Food & beverage$2,15624%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $7,161 |
| Argenx US, Inc. | 5 | $273 |
| EMD Serono, Inc. | 4 | $169 |
| SK Life Science, Inc. | 6 | $160 |
| Greenwich Biosciences, Inc. | 1 | $125 |
| Biogen | 7 | $118 |
| Avanir Pharmaceuticals, Inc. | 1 | $118 |
| Acadia Pharmaceuticals Inc | 4 | $90 |
| Sunovion Pharmaceuticals Inc. | 9 | $81 |
| Harmony Biosciences LLC | 2 | $75 |
| UCB, Inc. | 5 | $72 |
| AstraZeneca | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $33 |
| Amgen | 2 | $32 |
| Novartis | 2 | $27 |
| GE HealthCare | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Otto Bock Healthcare LP | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Neurelis, Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $15 |
| Aprecia Pharmaceuticals, LLC | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,809 in reported general payments places this provider in the 65th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 14 | $120,453 |
| EpidiolexCannabidiol (Cbd) | 11 | $62,320 |
| Nurtec OdtRimegepant Sulfate | 20 | $22,016 |
| Glatiramer Acetate | 12 | $16,617 |
| UbrelvyUbrogepant | 12 | $16,320 |
| Oxcarbazepine | 66 | $15,368 |
| QuliptaAtogepant | 12 | $14,502 |
| Lacosamide | 29 | $5,382 |
| Levetiracetam | 155 | $4,998 |
| Gabapentin | 153 | $4,511 |
| Divalproex Sodium | 21 | $4,348 |
| Memantine Hcl | 172 | $4,217 |
| Carbamazepine ErCarbamazepine | 16 | $3,861 |
| Divalproex Sodium ErDivalproex Sodium | 22 | $2,573 |
| Entacapone | 17 | $2,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $7,161 | $30,82224 claims |
| Upsher-smith Laboratories LLCTopiramate | $18 | $71761 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 neurology providers in Arizona.
Other neurology in Mesa
- David MarzuloMesa$38K
- Gilbert ToffolMesa$32K
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Nida LaurinScottsdale$969K
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.